Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma

Background Objective responses to immune checkpoint inhibitors (ICI) in leiomyosarcoma (LMS) are rare. Response rates may be increased by combination with other drugs known to promote immune infiltration, such as poly(ADP-ribose) polymerase (PARP) inhibitors, which have led to benefit in BRCA-altere...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert G Maki, Martina Bradic, Phillip Wong, William Tap, Vicky Makker, Sandra D’Angelo, Angela Green, Mrinal M Gounder, Evan Rosenbaum, Ciara M Kelly, Jason E Chan, Ping Chi, Mark A Dickson, Mary L Keohan, Sujana Movva, Viswatej Avutu, Martee L Hensley, Maria M Rubinstein, Ronak Shah, Kenneth Seier, Karmelina Charalambous, Seth M Cohen, Lauren B Banks, Sara Saunds, Jae-Mun Cho, Robert A Lefkowitz, Joseph Erinjeri, Li-Xuan Qin
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/6/e012020.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items